Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session reveal strong financial health, optimistic guidance, and significant progress in clinical trials. Enrollment is ahead of projections, and the company is on track with its BLA filing timeline. The positive market reaction is bolstered by the announcement of new drugs entering the market and strong patient and physician interest. Despite some management responses being unclear, the overall sentiment is positive, suggesting a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Cash, cash equivalents, and marketable securities $630.5 million as of June 30, 2025, compared to $861.7 million as of December 31, 2024. The decrease reflects the company's ongoing investments in its clinical pipeline and operational infrastructure.
Collaboration revenue $14.2 million during Q2 2025, compared to $6.9 million during the prior year quarter. This $7.3 million increase was mainly driven by cost reimbursements related to the collaboration with Regeneron Pharmaceuticals.
R&D expenses $97 million during Q2 2025, compared to $114.2 million during the prior year quarter. This $17.2 million decrease was primarily driven by reductions in employee-related expenses, stock-based compensation, research materials, and contracted services, offset by increased expenses for advancing lead programs.
Stock-based compensation in R&D expenses $14.1 million for Q2 2025.
G&A expenses $27.2 million during Q2 2025, compared to $31.8 million during the prior year quarter. This $4.6 million decrease was primarily related to lower stock-based compensation, offset in part by increased expenses for the ongoing build-out of commercial infrastructure.
Stock-based compensation in G&A expenses $8 million for Q2 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Lonvo-z for HAE: Expected to launch in the first half of 2027. Phase III studies are enrolling faster than expected, with recruitment completed and randomization expected in Q3 2025. Lonvo-z is positioned as a one-time therapy with a unique profile, offering freedom from attacks and chronic treatment.
Nex-z for ATTR Amyloidosis: Phase III studies are progressing well, with enrollment targets increased to 1,200 patients for cardiomyopathy trials. Nex-z shows potential as a differentiated competitor in the market, with strong clinical data supporting its efficacy in reducing TTR levels and improving patient outcomes.
ATTR Amyloidosis Market: Nex-z is positioned to be a formidable competitor in this large and growing market, with strong demand from patients and physicians.
HAE Market: Lonvo-z addresses a high unmet need, with significant interest from patients and physicians, indicating strong market potential.
Operational Efficiency: Phase III studies for Lonvo-z and Nex-z are enrolling faster than expected, reflecting operational excellence. The company has also built out its commercial and medical affairs leadership teams to support future product launches.
Financial Restructuring: Restructuring efforts have delivered expected benefits, supporting a financial runway into the first half of 2027.
Strategic Expansion: Enrollment targets for Nex-z cardiomyopathy trials increased to 1,200 patients to enhance data robustness and market competitiveness.
Leadership Transition: Chief Medical Officer David Lebwohl announced his retirement effective August 2026, with a successor search underway to ensure a seamless transition.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The expansion of the Phase III study for nex-z in ATTR cardiomyopathy to 1,200 patients is subject to health authority review, which could delay timelines or require additional resources.
Financial Risks: The company’s cash balance of $630.5 million is projected to fund operations only until the first half of 2027, which may necessitate additional funding or partnerships to sustain operations.
Operational Challenges: The rapid enrollment in multiple Phase III studies, while a positive indicator of demand, could strain operational resources and require careful management to maintain quality and timelines.
Market Competition: The TTR treatment landscape is evolving with new agents becoming available, which could impact the competitive positioning of nex-z.
Strategic Execution Risks: The company is undergoing a significant build-out of its commercial and medical teams, which introduces risks related to integration, execution, and alignment with strategic goals.
Clinical Trial Risks: The reliance on strong patient and physician interest for enrollment in trials could be impacted by unforeseen factors, potentially delaying study completion or affecting data quality.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Launch of Lonvo-z for HAE: The company expects to launch Lonvo-z for HAE in the first half of 2027.
Enrollment in Phase III studies: Enrollment for all three Phase III studies (Lonvo-z and Nex-z) is progressing faster than expected. The company anticipates completing enrollment earlier for HAE and ATTR polyneuropathy programs and enrolling more patients in the cardiomyopathy program than initially planned.
Expansion of Nex-z Phase III study: The company plans to increase enrollment in the Nex-z Phase III study for ATTR cardiomyopathy to approximately 1,200 patients, subject to health authority review, to provide a more robust data set.
Completion of Magnitude enrollment: The company aims to complete Magnitude enrollment by early 2027.
Completion of HAELO study recruitment: Recruitment for the HAELO study of Lonvo-z has ended, and randomization is expected to be completed during the third quarter of 2025.
Completion of Magnitude 2 enrollment: Enrollment for the Magnitude 2 study for hereditary ATTR polyneuropathy is expected to be completed in the first half of 2026.
Regulatory milestones: The company plans to achieve several clinical and regulatory milestones before the end of 2026.
Financial guidance: The company expects a year-over-year decline in GAAP operating expenses by approximately 10% in 2025 and has sufficient cash to fund operations into the first half of 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Now that you've increased the target number for the ATTR-CM study, do you have a target proportion of patients you would like to be on stabilizers to be powered to see the benefit in combination?
A:The study initially estimated 50-60% of patients on stabilizers, but now expects around 70% due to stabilizers becoming the standard of care. This is not a target number but reflects real-world usage. The study aims for statistically significant findings for both the overall group and the combination of nex-z with stabilizers.
Q:How will the cash runway be impacted by the trial expansion?
A:The company takes a conservative approach to financial planning. The increase to 1,200 patients represents a modest and immaterial uptick in costs, which can be absorbed without impacting the cash runway or net cash burn guidance through 2025 and 2026.
Q:What are the latest assumptions on Phase III events accrual rate for nex-z, and did this prompt the study expansion to 1,200 patients?
A:Specific event rates were not disclosed. The decision to expand was based on competitor data, databases, and Phase I patient data, which suggest lower event rates due to deep, rapid, and sustained TTR reduction. The expansion aims to ensure robust outcomes for both the overall group and patients on stabilizers.
Q:Why is the enrollment pace for your TTR cardiomyopathy trial slower compared to AstraZeneca's trial?
A:The trials differ significantly. AstraZeneca's trial included all patients, even very sick ones, and those on any therapy. Intellia's trial has stricter criteria. Despite new drugs entering the market, enrollment has increased, showing strong interest from patients and physicians.
Q:How will you maintain study blindness for lonvo-z given its binary response?
A:The trial uses standard blinding procedures where neither patients nor physicians know the treatment. While patients may experience different outcomes, this does not constitute unblinding. The study measures discrete clinical events, ensuring integrity.
Q:Have changes in enrollment expectations or stabilizer percentage affected the likelihood or timing of an interim readout?
A:The adjustments increase the study's power for both the primary outcome and the TAP subgroup. These changes are expected to favorably affect the ability to find an effect during an interim analysis.
Q:What specific data are you trying to generate to show compelling information to payers and physicians?
A:The study aims to show a significant and clinically meaningful benefit of nex-z over stabilizers, which has not been demonstrated by other drugs. The expansion allows for faster accumulation of events and more robust data to differentiate the product in the market.
Q:What level of progression would you expect to see in functional measures for Phase I ATTR-CM patients?
A:Phase I data shows a 90% reduction in TTR levels within a month, stabilization or improvement in functional measures like proBNP and 6-minute walk, and low event rates despite high-risk patients. This is unprecedented compared to historical data.
Q:What are your thoughts on potential drivers of grade 4 LFT changes following lengthy treatments?
A:A previously reported transaminase elevation was mild (grade 1), asymptomatic, and resolved without therapy. The patient continues in the study. The cause is under investigation, but it is unlikely to be directly related to LNPs.
Q:Is the MAGNITUDE study now powered to show statistical significance in the subset on stabilizer background?
A:Yes, the study is now powered to show statistical significance in the subset on stabilizer background.
Q:What are the qualities of patients opting for gene editing studies, and what proportion of the market might be open to permanent options?
A:Patients meet standard inclusion/exclusion criteria and are not in desperate situations. Many choose to participate despite available therapies, indicating strong interest in permanent solutions. The notion of a permanent fix is embraced by both patients and physicians.
Q:Why is 1,200 the right number for the MAGNITUDE study, and is this final?
A:The number balances faster event accumulation with manageable enrollment time. It aligns with Phase I data suggesting a benefit in the stabilizer population and maintains the cash runway. No further adjustments are planned.
Q:Did you consider differences between first-generation and newly approved stabilizers or silencers in your statistical planning?
A:Second-generation stabilizers are considered equivalent to tafamidis. The study accounts for potential switches from tafamidis to vutrisiran and anticipates some patients choosing silencers, but this does not impact the ability to achieve positive results.
Q:What are your thoughts on the commercial setup for gene editing therapies, especially in HAE?
A:The company expects pricing to align with precedents and aims for win-win pharmacoeconomics. Payers are expected to respond positively to the ease of use and excellent outcomes of outpatient infusion therapies. The unique benefits of permanent solutions are emphasized.
Q:How does the competitive landscape for nex-z impact its commercial positioning?
A:The strong results of competing RNAi therapies confirm the large, underdiagnosed market. Nex-z is positioned as a formidable competitor, particularly for wild-type cardiomyopathy patients, who represent about 90% of the market.
Q:What are your thoughts on the launch of another Kallikrein knockdown therapy and its implications for lonvo-z?
A:Lonvo-z offers unique benefits as a permanent solution with excellent clinical performance and no need for ongoing therapy. It is expected to be a formidable competitor due to its ability to provide freedom from disease and ease of care for physicians.
Q:Why is 1,200 the right number for the MAGNITUDE study, and is this final?
A:The number balances faster event accumulation with manageable enrollment time. It aligns with Phase I data suggesting a benefit in the stabilizer population and maintains the cash runway. No further adjustments are planned.
Q:Review of Unclear Management Responses
A:Management avoided providing specific event rates for Phase III assumptions and did not attribute a specific mechanism to the reported transaminase elevation. Additionally, they did not provide detailed statistics for the MAGNITUDE study's power calculations or elaborate on the proportion of patients open to permanent gene editing options.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chaves
Co
Head
III study
Inc Research
LLC Research
Lonvo
Phase II
Phase III
Research Division
TTR treatment
advantage
affair
attack freedom
authority review
body evidence
clinician payer
combination stabilizer
compensation expense
demand study
freedom attack
health authority
infusion reaction
magnitude patient
milestone
need HAE
nex combination
onetime
patient clinician
potential freedom
proposition lonvo
sample size
stability
successor
NTLA Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call revealed an increase in revenue but also a widening net loss due to higher R&D expenses. The cash reserves are decreasing, raising concerns about financial sustainability. The Q&A section did not provide clarity on management's responses, which may contribute to uncertainty. Despite a positive revenue growth, the financial health and lack of strategic updates suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8%.
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call highlights several concerns: unclear management responses to critical questions, ongoing clinical hold, and lack of precise financial guidance. Despite some positive aspects like reduced net loss and strategic financing options, the uncertainty surrounding safety events and potential regulatory challenges outweigh the positives. Given the company's market cap, the stock price is likely to experience a negative reaction in the short term.
NTLA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
